The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas

Most pituitary adenomas (PAs) are considered benign tumors, but approximately 0.2% can present metastasis and are classified as pituitary carcinomas (PCs). Refractory PAs lie between benign adenomas and true malignant PC and are defined as aggressive-invasive PAs characterized by a high Ki-67 index,...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Congxin, Liang, Siyu, Sun, Bowen, Kang, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761748/
https://www.ncbi.nlm.nih.gov/pubmed/33362722
http://dx.doi.org/10.3389/fendo.2020.608422

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761748/
https://www.ncbi.nlm.nih.gov/pubmed/33362722
http://dx.doi.org/10.3389/fendo.2020.608422

Ejemplares similares